Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc faces legal challenges and financial uncertainty, including a securities class action lawsuit alleging securities fraud, which has led to significant stock price volatility.

Actinium Pharmaceuticals Inc. presents promising preclinical data for its lead product candidate, Actimab-A, which shows potential as a mutation-agnostic therapy for acute myeloid leukemia (AML).